AzTrials
AzTrials

Atrial Fibrillation (AF)FLASH AFNCT07779213

Detection of Atrial Fibrillation Using PPG From Smartphone Cameras

An observational study of Atrial Fibrillation (AF), run by Happitech BV at 5 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Read more about this study

Who is it for?
Ages 22 minutes and older
Conditions the study is for
Atrial Fibrillation (AF)
What is being tested?
12 Lead ECG is compared to a smartphone based PPG
How many people
554 participants
Where
5 sitesin 2 countries
Study dates
30 Jun 2026to Nov 2026
How long will I take part?
1 Day
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 minutes and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Male and female patients aged 22 years or older who are cardiology patients consulting the cardiac outpatient clinic, 50% of whom have a rhythm of atrial fibrillation at the time of enrollment, and own a smartphone.

Who may be able to join

  • Adults aged 22 years or older
  • Owns a smartphone and knows how to operate and navigate different applications.
  • Individuals able to read, understand, and sign the consent form.
  • Cardiology patients consulting the cardiac outpatient clinic.
  • History of persistent AF or other cardiac rhythm

Who cannot join

  • Participants with cognitive impairments
  • Individuals who cannot read, speak, and/or understand English
  • Patients with implantable neurostimulators, cardiac implantable device in an atrial or ventricular paced rhythm documented on a 12-lead ECG during the initial study visit

Trial locations and contacts

5 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Yosef Safi Harb, CEO contact

+31 (0) 681885565

yosef@happitech.com

Amanda Marinov, Regulatory contact

+359878422979

a.marinov@happitech.com

5 sites in 2 countries

United States4 sites, 4 recruiting
  • Nair Research, LLC dba Arrhythmia Research Group LLC

    Jonesboro, Arkansas, 72401

    Kayla Rubino, 870-340-7387, krubino@drnairresearch.com

    Devi Nair, Doctor

    Recruiting
  • South Denver Cardiology

    Littleton, Colorado, 80210

    Kathy Siegel, Clinical Research Director, 720-217-6139, ksiegel@southdenver.com

    Srikanth Sundaram, Doctor

    Recruiting
  • Tulane University

    New Orleans, Louisiana, 70112

    Kunal Sameer, Associate Director of Ops, 203-285-5666, ksameer@tulane.edu

    Nassair Marrouchi, Doctor

    Not yet recruiting
  • CardioVascular Health Clinic

    Oklahoma City, Oklahoma, 73134

    Sophie Haynes, Regulatory Director, 405-696-0007, sophie@hightowerclinical.com

    Monica Lo, Doctor

    Recruiting

Other trials in United States

Netherlands1 site, 1 recruiting
  • Isala Zwolle

    Zwolle, Overijssel, 8025 AB

    Fleur van Haveren, Research Cardiology, 088 6248377, f.van.haveren@isala.nl

    Sebastien Krul, Doctor

    Recruiting

Other trials in Netherlands

About this study

Official title: Detection of Atrial Fibrillation Using Photoplethysmography From Smartphone Cameras

The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Algorithm output will be compared to a gold standard of 12-lead ECG recorded with a simultaneous PPG measurement.

Read the detailed description

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is increasing and is expected to continue increasing for decades,. Detection of AF episodes may be useful for the identification of undiagnosed AF and in making clinical management decisions that include oral anticoagulation, restoration and maintenance of sinus rhythm, control of ventricular rate, and risk factor modification. Treatment of AF is associated with improvements of quality of life, stroke prevention, and reduced risk of heart failure.

Traditionally, diagnosis of AF is done using an electrocardiogram, with low amplitude or absent p-waves and narrow complex "irregularly irregular" pattern intervals seen on the ECG,. After diagnosis, there are a variety of methods that can be used to manage AF. Ambulatory ECG monitoring, implantable monitoring devices, and over-the-counter wrist-worn devices have been used to manage patients with AF,,. However, these devices are inconvenient and expensive which limits their wide adoption into clinical practice. There is an unmet clinical need for an easy to use and inexpensive over-the-counter FDA-cleared products that can detect episodes of AF in real-time and notify patients to seek out further care when AF is suspected.

Recent technological advancements have allowed for the identification of AF using smartwatches, with device manufacturers gaining over-the-counter regulatory clearance for their irregular heart rate detection algorithms,. These wrist-worn devices use a light-based measurement method called photoplethysmography (PPG) to measure changes in light absorbance and reflectance to understand changes in blood flow in superficial vasculature. The waveform generated from this measurement can be used to measure parameters like pulse rate, respiratory rate, pulse rate variability and others in addition to detecting AF. The increasing ubiquity of smartphones worldwide has led to greater availability of heart rhythm diagnostics using smartphone photoplethysmography (PPG). Smartphone camera PPG technology uses the light-emitting diode in cameras to measure pulsatile changes in light intensity that are reflected from a finger and can be used to detect AF. The widespread availability of this technology has the potential to improve the accessibility and convenience of heart rhythm monitoring, particularly in remote or underserved areas. This could result in improvements in early detection and management of AF, leading to better patient outcomes. Several smartphone PPG-based algorithms have been developed that utilize smartphones' built-in cameras to detect AF. The sensitivity and specificity of these algorithms for the detection of AF range between 81%-100% and 85%-100% respectively. However, there is a lack of evidence regarding the performance of these algorithms in detecting AF in an out-of-hospital setting using a gold-standard reference.

Happitech has developed a proprietary software development kit (SDK) that can be utilized to measure patients' cardiovascular parameters and identify potential pathologies including AF. Happitech's algorithm requires users to place a digit directly against their phone camera, and the camera and underlying algorithm detect subtle differences in blood flow to calculate physiological parameters for monitoring and clinical use.

The purpose of this study is to validate the performance of Happitech's PPG-based algorithm for the detection of AF against a 12-lead ECG in a diverse population of patients including cardiology patients being evaluated as inpatients or at a cardiology clinic visit.

Being tested
12 Lead ECG is compared to a smartphone based PPG
Keywords
wearables, smartphone based ppg, ppg, digital health, health equity, atrial fibrillation, healthtech, cardiac monitoring
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12 Lead ECG is compared to a smartphone based PPGDiagnostic test

    12 Lead ECG is compared to a smartphone based PPG

Study groups in NCT07779213
Study groupRoleWhat they receive
Sinus RhythmPatient visiting the Cardiology Clinic in Sinus Rhythm
Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG
Atrial FibrillationPatient visiting the Cardiology Clinic in Atrial Fibrillation
Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG
OtherPatient visiting the Cardiology Clinic with neither Sinus Rhythm or Atrial Fibrillation
Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To evaluate the sensitivity and specificity of the Heart Rhythm Software

    To evaluate the sensitivity and specificity of the Heart Rhythm Software algorithm running on a commercially available smartphone to detect atrial fibrillation segments using photoplethysmography (PPG) as measured through the phone's camera.

    Se is defined as the percentage of patients with 90 second interval recordings scored by the Heart Rhythm Software algorithm as AF, out of all intervals determined by the Clinical Adjudication Committee (CAC) to be AF (gold standard).

    Sp is defined as the percentage of patients with 90 second intervals scored by the Heart Rhythm Software algorithm as NSR out of all ECG recordings determined by the CAC to be NSR.

    Measured: Through study completion, an average of 6 months

Secondary outcomes (1)
  1. Sensitivity & Specificity across subgroups

    The accuracy of the Happitech Heart Rhythm Software algorithm in detecting irregular rhythm suspected of AF and regular rhythm suspected normal sinus rhythm will be further investigated in subgroups defined by ethnicity, race, BMI, age group, smartphone type, and Fitzpatrick scale score. The sensitivity and specificity will be presented as an estimate and associated 95% CI's, as well as a Chi-square or Fisher's Exact p-value to assess if all levels of the subgroup are homogeneous.

    Measured: through study completion, an average of 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2026
  2. Study start30 Jun 2026
  3. Primary completionNov 2026 (estimated)
  4. Study completionNov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
554 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07779213
Sponsor's protocol ID
HAPP-CTP-FDA-2025-002
Acronym
FLASH AF
Status last verified
Aug 2026
First submitted
11 Aug 2026
Last updated
21 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in